Abhilash Deo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abhilash Deo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Yuval Shaked
Technion
54 shared publications - Alona Zer
Rambam Healthcare Campus 9 Department of Oncology Haifa, Israel
53 shared publications - Anat Grinfeld
Department of Radiology Rambam Healthcare Campus 7 , Haifa, Israel
53 shared publications - Ayelet Eran
Department of Radiology Rambam Health Care Campus , Haifa 3525408
53 shared publications - Bar Manobla
Technion - Israel Institute of Technology 1 Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine Haifa, Israel
53 shared publications - Chen Buxbaum
Technion - Israel Institute of Technology 1 Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine Haifa, Israel
53 shared publications
Latest Publications
- Open Access
The coumarin derivative X6632 is a pan-ID protein inhibitor that suppresses tumor growth by targeting cancer cells and the tumor-associated microvasculature
Inhibitor of DNA binding (ID) proteins are key regulators of tumor cell stemness, therapy resistance and pathological angiogenesis in multiple cancer types and other diseases. Here, we characterize the coumarin-derived compound X6632 as a pan-ID inhibitor with dual activity against tumor cells and the tumor-associated microvasculature in a number of human and murine models. X6632 efficiently suppressed ID protein expression, inhibited the proliferation, migration, invasion of melanoma cells, and impaired multiple endothelial cell functions, including proliferation, migration, invasion, tube formation and sprouting in vitro. In back-to-back comparisons, X6632 exhibited an approximately ten-fold higher efficacy compared to the first-generation ID antagonist AGX51. In vivo, X6632 potently reduced pathological (neo)vascularization in established angiogenesis models, including oxygen-induced retinopathy and in Matrigel plug assays. It also significantly decreased blood vessel density in syngeneic melanoma models, delayed tumor growth and, when combined with immune checkpoint blockade, achieved superior tumor control compared with either monotherapy. Moreover, X6632 inhibited clonogenic growth in several breast cancer models, and robustly suppressed the growth of triple negative breast cancer in vivo, both in the highly aggressive 4T1 syngeneic model and in patient-derived xenografts. Collectively, these data establish X6632 as a second-generation, pan-ID protein inhibitor that can simultaneously target malignant cells and the tumor-supporting vasculature, and support the further pre-clinical development of the compound for the treatment of melanoma, breast cancer and potentially additional ID-dependent malignancies, as well as diseases driven by pathological neoangiogenesis.
Open AccessThe coumarin derivative X6632 is a pan-ID protein inhibitor that suppresses tumor growth by targeting cancer cells and the tumor-associated microvasculature
Inhibitor of DNA binding (ID) proteins are key regulators of tumor cell stemness, therapy resistance and pathological angiogenesis in multiple cancer types and other diseases. Here, we characterize the coumarin-derived compound X6632 as a pan-ID inhibitor with dual activity against tumor cells and the tumor-associated microvasculature in a number of human and murine models. X6632 efficiently suppressed ID protein expression, inhibited the proliferation, migration, invasion of melanoma cells, and impaired multiple endothelial cell functions, including proliferation, migration, invasion, tube formation and sprouting in vitro. In back-to-back comparisons, X6632 exhibited an approximately ten-fold higher efficacy compared to the first-generation ID antagonist AGX51. In vivo, X6632 potently reduced pathological (neo)vascularization in established angiogenesis models, including oxygen-induced retinopathy and in Matrigel plug assays. It also significantly decreased blood vessel density in syngeneic melanoma models, delayed tumor growth and, when combined with immune checkpoint blockade, achieved superior tumor control compared with either monotherapy. Moreover, X6632 inhibited clonogenic growth in several breast cancer models, and robustly suppressed the growth of triple negative breast cancer in vivo, both in the highly aggressive 4T1 syngeneic model and in patient-derived xenografts. Collectively, these data establish X6632 as a second-generation, pan-ID protein inhibitor that can simultaneously target malignant cells and the tumor-supporting vasculature, and support the further pre-clinical development of the compound for the treatment of melanoma, breast cancer and potentially additional ID-dependent malignancies, as well as diseases driven by pathological neoangiogenesis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Log2-fold change in the levels of circulating plasma proteins in BALB/c mice treated with anti-PD1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Log2-fold change in the levels of circulating plasma proteins in BALB/c mice treated with anti-PD1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Depletion of CD8+ T cells expressing DKK1 restores BBB function and mitigates BrM. Eight-week-old SCID mice were treated with LPS, IgG, or anti–PD-1. After 1 week, mice were perfused with EB, and subsequently, brains were harvested. A, Representative images of EB-perfused brains (n = 4–5 mice/group). Absorbance of EB dye extracted per gram of brain tissue is plotted. B, Representative immunofluorescence images showing colocalization of CD31 (blood vessels, red) and EB (green) in the brains from the different groups. Extravasation of EB per field is plotted. Scale bars, 20 µm. C, DKK1 levels were analyzed using a specific ELISA in the conditioned medium of CD4+ T, CD8+ T, and B cells harvested from the spleens of IgG and anti-PD-1–treated EMT6 tumor–bearing BALB/c mice. D, Representative immunofluorescence images showing colocalization of granzyme B (green) and DKK1 (red) in CD8+ T cells harvested from IgG and anti-PD-1–treated BALB/c mice. The colocalization coefficient is plotted. Scale bars, 10 µm. E and F, Adoptive transfer of wild-type (Vector) and Dkk1-KD [guide RNA (gRNA)] CD8+ T cells obtained from BALB/c mice was performed on 8-week-old SCID mice, followed by IgG or anti–PD-1 treatment. At the endpoint, the mice were perfused with EB dye. A scheme of the experimental design is illustrated (E). Representative images of EB-perfused brains taken from mice under the same treatment groups (n = 4 mice/group) are shown, and the absorbance of EB dye extracted per gram of brain tissue is plotted (F). Significance was assessed using one-way ANOVA for A–C and F and Student t test for D (*, P < 0.05; ***, P < 0.001). [E, Created in BioRender. Raviv, Z. (2026) https://BioRender.com/rwrqpz8.]
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Depletion of CD8+ T cells expressing DKK1 restores BBB function and mitigates BrM. Eight-week-old SCID mice were treated with LPS, IgG, or anti–PD-1. After 1 week, mice were perfused with EB, and subsequently, brains were harvested. A, Representative images of EB-perfused brains (n = 4–5 mice/group). Absorbance of EB dye extracted per gram of brain tissue is plotted. B, Representative immunofluorescence images showing colocalization of CD31 (blood vessels, red) and EB (green) in the brains from the different groups. Extravasation of EB per field is plotted. Scale bars, 20 µm. C, DKK1 levels were analyzed using a specific ELISA in the conditioned medium of CD4+ T, CD8+ T, and B cells harvested from the spleens of IgG and anti-PD-1–treated EMT6 tumor–bearing BALB/c mice. D, Representative immunofluorescence images showing colocalization of granzyme B (green) and DKK1 (red) in CD8+ T cells harvested from IgG and anti-PD-1–treated BALB/c mice. The colocalization coefficient is plotted. Scale bars, 10 µm. E and F, Adoptive transfer of wild-type (Vector) and Dkk1-KD [guide RNA (gRNA)] CD8+ T cells obtained from BALB/c mice was performed on 8-week-old SCID mice, followed by IgG or anti–PD-1 treatment. At the endpoint, the mice were perfused with EB dye. A scheme of the experimental design is illustrated (E). Representative images of EB-perfused brains taken from mice under the same treatment groups (n = 4 mice/group) are shown, and the absorbance of EB dye extracted per gram of brain tissue is plotted (F). Significance was assessed using one-way ANOVA for A–C and F and Student t test for D (*, P < 0.05; ***, P < 0.001). [E, Created in BioRender. Raviv, Z. (2026) https://BioRender.com/rwrqpz8.]
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Dkk1 knockdown in CD8+ T cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Dkk1 knockdown in CD8+ T cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Clinicopathological features of patients of prospective study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Clinicopathological features of patients of prospective study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Clinicopathological features of patients of retrospective study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Clinicopathological features of patients of retrospective study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Validation of scRNA-seq data using flow cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Validation of scRNA-seq data using flow cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
β-Catenin/TCF and FOXM1 signaling regulate Dkk1 expression in CD8+ T cells. CD8+ T cells were isolated from the spleens of 8-week-old C57BL/6 mice, activated with phorbol 12-myristate 13-acetate (PMA; 10 ng/mL) and ionomycin (10 µg/mL), and cocultured with LLC tumor cells under various ICI-treated conditions, as indicated in the figure. A, Secretory levels of granzyme B and DKK1 in the conditioned media of CD8+ T cells were measured using specific ELISA. B, Flow cytometry was performed to assess activated CD8+ T cells (CD45+CD8+granzyme B+) and DKK1+ activated CD8+ T cells (CD45+CD8+granzyme B+DKK1+). C, CD8+ T cells were isolated and activated with PMA and ionomycin and cultured under various ICI-treated conditions, as indicated in the figure. Cells were assessed for RNA expression of various factors, as indicated in the figure, using real-time PCR. D and E, CD8+ T cells were isolated and activated with PMA and ionomycin, followed by treatments with a FOXM1 inhibitor (FDI-6; 30 µM), a β-catenin/TCF inhibitor (PKF118-310; 1 µM), a combination of both, or a vehicle control (DMSO) for 24 hours. After treatment, cells were harvested to analyze (D) Dkk1 expression by real-time PCR and (E) DKK1 secretion levels (from conditioned medium) using a specific ELISA (the dotted line represents the detection limit). F, Illustration summarizing that anti–PD-1 blockade activates CD8+ T cells, leading to increased Dkk1 expression and secretion via β-catenin/TCF and FOXM1 signaling pathways. Secreted DKK1 impairs endothelial barrier integrity by suppressing WNT/β-catenin signaling, resulting in the downregulation of adherens junction (VE-cadherin) and tight junction proteins (claudin-5 and occludin), thereby increasing BBB permeability. Significance was assessed using one-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001). [F, Created in BioRender. Raviv, Z. (2026) https://BioRender.com/rod21ab.]
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
β-Catenin/TCF and FOXM1 signaling regulate Dkk1 expression in CD8+ T cells. CD8+ T cells were isolated from the spleens of 8-week-old C57BL/6 mice, activated with phorbol 12-myristate 13-acetate (PMA; 10 ng/mL) and ionomycin (10 µg/mL), and cocultured with LLC tumor cells under various ICI-treated conditions, as indicated in the figure. A, Secretory levels of granzyme B and DKK1 in the conditioned media of CD8+ T cells were measured using specific ELISA. B, Flow cytometry was performed to assess activated CD8+ T cells (CD45+CD8+granzyme B+) and DKK1+ activated CD8+ T cells (CD45+CD8+granzyme B+DKK1+). C, CD8+ T cells were isolated and activated with PMA and ionomycin and cultured under various ICI-treated conditions, as indicated in the figure. Cells were assessed for RNA expression of various factors, as indicated in the figure, using real-time PCR. D and E, CD8+ T cells were isolated and activated with PMA and ionomycin, followed by treatments with a FOXM1 inhibitor (FDI-6; 30 µM), a β-catenin/TCF inhibitor (PKF118-310; 1 µM), a combination of both, or a vehicle control (DMSO) for 24 hours. After treatment, cells were harvested to analyze (D) Dkk1 expression by real-time PCR and (E) DKK1 secretion levels (from conditioned medium) using a specific ELISA (the dotted line represents the detection limit). F, Illustration summarizing that anti–PD-1 blockade activates CD8+ T cells, leading to increased Dkk1 expression and secretion via β-catenin/TCF and FOXM1 signaling pathways. Secreted DKK1 impairs endothelial barrier integrity by suppressing WNT/β-catenin signaling, resulting in the downregulation of adherens junction (VE-cadherin) and tight junction proteins (claudin-5 and occludin), thereby increasing BBB permeability. Significance was assessed using one-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001). [F, Created in BioRender. Raviv, Z. (2026) https://BioRender.com/rod21ab.]
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Association of longitudinal increase in plasma DKK1 levels with brain metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
Association of longitudinal increase in plasma DKK1 levels with brain metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
DKK1 in plasma from anti-PD1 treated mice disrupts the integrity of endothelial cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from PD-1 Blockade–Induced DKK1 Expression by CD8+ T Cells Promotes Blood–Brain Barrier Permeabilization
DKK1 in plasma from anti-PD1 treated mice disrupts the integrity of endothelial cells